Umlazi CRS
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Govender, Vani
MOCHA, NCT03497676: More Options for Children and Adolescents (): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

Active, not recruiting
1/2
168
US, RoW
Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Edurant, Long-Acting Injectable Cabotegravir (CAB LA), Long-Acting Injectable Rilpivirine (RPV LA), Combination Antiretroviral Therapy (cART)
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
02/23
06/25
NCT05406583: A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

Recruiting
1
36
US, RoW
Dolutegravir 0.5 mg/kg oral suspension, DTG, Dolutegravir 5 mg Dispersible Tablets
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
HIV
09/25
11/25

Download Options